Intra-Cellular Therapies' main drug, Caplyta, has been successful in treating neuropsychiatric conditions and has shown potential in addressing mixed features in mood disorders. Q2 2023 earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results